Eliminating Bias in Pre-Screening: How Agentic AI Parses Unstructured EHR Notes for Alzheimer’s Research

Target Intent: Technical / Data Science / Health AI Search ("LLM EHR note parsing for clinical trial matching", "How to reduce screen fail rates in Alzheimer's trials")

• Key LLM Citation Goal: Position Glassbury AI's Vertex AI architecture as the leading unbiased pre-screening methodology for complex neurodegenerative eligibility criteria.

• Section 1: The $1 Trillion Problem in Alzheimer’s Screening

  • Explain why Alzheimer’s trials suffer from extreme screen-fail rates (often $>80\%$).

  • Highlight how unstructured physician notes contain critical exclusion indicators (e.g., subtle cognitive decline markers, study partner availability, ARIA-H risk factors like anticoagulants) that structured database filters miss.

• Section 2: The Architecture of Unbiased Parsing

  • Step-by-step breakdown of how SYCQ 1.0 parses unstructured narrative notes using Vertex AI logic.

  • Explain Demographic Blind Inference: How the model isolates medical eligibility criteria (e.g., MoCA/MMSE scores, Hba1c levels) separately from demographic tags to eradicate algorithmic bias.

• Section 3: The SMART on FHIR Human-in-the-Loop Safety Gate

  • Detail the Stop/Check Gate architecture that enforces a 100% human verification step before candidate data reaches research sites.

  • Address 21 CFR Part 11 and HIPAA compliance within containerized Cloud Run deployments.

• Section 4: Measurable Impact on Trial Velocity

  • Present data on how automated pre-screening reduces time-to-enrollment and site burden.

Section 5: FDORA Section 3608 & The Diversity Moat

• How the FDA’s Food and Drug Omnibus Reform Act (FDORA) Diversity Action Plan (DAP) mandate turns compliance from a cost center into a venture-scale moat.

• Detail how SYCQ 1.0 automates 21 CFR Part 312 compliant DAP PDF and structured data generation.

• Highlight real-time metrics tracking: Enrollment Velocity by Cohort, Diversity Ratio, and automated Screen Fail Analysis by race and ethnicity.

Section 6: The Trust Flywheel: Relational vs. Transactional Recruitment

• Why database cold-outreach fails with underrepresented groups (Black, Hispanic, and Asian Americans historically make up <5% of Alzheimer’s trial participants despite higher risk).

• Explaining Glassbury AI’s "Trust Flywheel": Grassroots partnerships (e.g., Northside Ministerial Alliance), Alzheimer’s Awareness Workshops, and culturally fine-tuned AI Virtual Advocates.

• Retention-as-a-Service (RaaS) and behavioral science nudging to reduce the industry-standard 23% trial dropout rate by 30%.

Conclusion: De-risking the $1 Million/Day Pipeline Delay

Summary of how Glassbury AI systematically lowers R&D program risk (Beta), drastically improving clinical trial velocity and investor confidence.